Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in COVID-19-Associated ARDS (RUXCOVID-DEVENT)
NCT04377620Phase 3Terminated
- Sponsor
- Incyte
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ruxolitinib in COVID-19-associated acute respiratory distress syndrome (CARDS), sponsored by Incyte. Started May 2020; status: terminated.
02
Drugs
03
Conditions
COVID-19-associated acute respiratory distress syndrome (CARDS)
Beyond the preview
Go deeper on NCT04377620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04377620.